Comment | Published:

The impact of mergers on pharmaceutical R&D

Nature Reviews Drug Discovery volume 10, pages 559560 (2011) | Download Citation

Abstract

Mergers and acquisitions in the pharmaceutical industry have substantially reduced the number of major companies over the past 15 years. The short-term business rationale for this extensive consolidation might have been reasonable, but at what cost to research and development productivity?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–214 (2010).

  2. 2.

    Rebuilding the R&D engine in Big Pharma. Harvard Bus. Rev. 86, 68–76 (2008).

  3. 3.

    Lessons from 60 years of pharmaceutical innovation. Nature Rev. Drug Discov. 8, 959–968 (2009).

Download references

Author information

Affiliations

  1. John L. LaMattina is the former President of Pfizer Global Research and Development, and is currently Senior Partner at Puretech Ventures, Boston, Massachusetts 02116, USA.  john.lamattina@comcast.net

    • John L. LaMattina

Authors

  1. Search for John L. LaMattina in:

Competing interests

The author declares no competing financial interests.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (figure)

    Approvals of new chemical entities by the US FDA: 1940–2010

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd3514

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing